BioCryst Pharmaceuticals
BCRX
274 hedge funds and large institutions have $1.32B invested in BioCryst Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 109 increasing their positions, 71 reducing their positions, and 24 closing their positions.
99% more call options, than puts
Call options by funds: $9.58M | Put options by funds: $4.8M
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
54% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 71
6% more funds holding
Funds holding: 258 → 274 (+16)
2.69% more ownership
Funds ownership: 80.95% → 83.64% (+2.7%)
4% more capital invested
Capital invested by funds: $1.26B → $1.32B (+$56.6M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$24.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17.4M |
| 3 |
D.E. Shaw & Co
New York
|
+$10.3M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$7.83M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$25.5M |
| 2 |
DM
Deerfield Management
New York
|
-$23.8M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$19.8M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$16.1M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$4.03M |
BCRX Hedge Fund Activity: Q1 2025 in Review
274 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2025, worth a combined $1.32B — up 4.5% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new BCRX positions and 24 closed out — a net gain of 17 holders — while 109 added to existing stakes and 71 trimmed.
The largest buyer was Millennium Management, adding an estimated $24.4M. The largest seller was Avoro Capital Advisors, cutting an estimated $25.5M.
- 274 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2025, up from 258 in Q4 2024.
- Funds reported $1.32B of BioCryst Pharmaceuticals stock for Q1 2025, up 4.5% quarter-over-quarter.
- 41 funds opened new BioCryst Pharmaceuticals positions in Q1 2025 and 24 closed out, a net change of +17 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $24.4M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2025 was Avoro Capital Advisors, an estimated $25.5M sold.
Based on aggregated 13F filings for Q1 2025.